Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trial.
Twenty-five patients with progressive, cisplatin-resistant epithelial ovarian cancer received 5-Fluorouracil (5-FU) 500 mg/m2 days one through three and Mitomycin-C 10 mg/m2 every 28 days in a phase II trial. Myelotoxicity manifested as thrombocytopenia resulted in dose reduction, delay of therapy, or discontinuation of treatment in 24% of patients. Only two patients (8%) demonstrated a partial response to therapy. Neither response was durable. The majority of patients (76%) demonstrated progression of disease following a single course of therapy. As utilized in this trial, the combination of 5-FU and Mitomycin-C is not an active salvage regimen for patients with cisplatin-resistant, progressive epithelial ovarian cancer.
Hempling
R E
RE
Department of Gynecologic Oncology, Roswell Park Cancer Institute.
Piver
M S
MS
Baker
T R
TR
O'Neill Mullen
C
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage*; D018283:Cystadenocarcinoma, Papillary / Q000188:drug therapy; D004351:Drug Resistance; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D016879:Salvage Therapy; D013921:Thrombocytopenia / Q000139:chemically induced
D018394:CA-125 Antigen; D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil